PriceTargets.com logo

Applied Therapeutics - APLT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.50
  • Forecasted Upside: 32.56%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$9.43 As of 11/20/2024 01:00 AM ET
▲ +0.5 (5.60%)

This chart shows the closing price for APLT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Applied Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APLT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APLT

Analyst Price Target is $12.50
▲ +32.56% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Applied Therapeutics in the last 3 months. The average price target is $12.50, with a high forecast of $14.00 and a low forecast of $11.00. The average price target represents a 32.56% upside from the last price of $9.43.

This chart shows the closing price for APLT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Applied Therapeutics. This rating has held steady since July 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/19/2024CitigroupBoost TargetBuy ➝ Buy$8.00 ➝ $11.00
9/19/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$11.00 ➝ $14.00
8/30/2024William BlairUpgradeStrong-Buy
8/27/2024CitigroupBoost TargetBuy ➝ Buy$7.00 ➝ $8.00
7/31/2024William BlairInitiated CoverageOutperform
7/17/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$12.00 ➝ $12.00
4/11/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$12.00
3/26/2024Royal Bank of CanadaInitiated CoverageOutperform$12.00
3/15/2024UBS GroupBoost TargetBuy ➝ Buy$12.00 ➝ $13.00
3/6/2024UBS GroupBoost TargetBuy ➝ Buy$4.00 ➝ $12.00
2/22/2024Leerink PartnrsReiterated RatingOutperform
2/22/2024Leerink PartnersInitiated CoverageOutperform$12.00
2/16/2024CitigroupBoost TargetBuy ➝ Buy$5.00 ➝ $7.00
4/25/2023Robert W. BairdLower Target$18.00 ➝ $14.00
4/5/2023CitigroupLower TargetBuy$23.00 ➝ $5.00
8/17/2022CitigroupLower TargetBuy$29.00 ➝ $23.00
8/16/2022BarclaysLower TargetEqual Weight$2.50 ➝ $2.25
5/20/2022CitigroupLower TargetBuy$29.00
4/13/2022Truist FinancialLower Target$6.00
3/21/2022BarclaysLower TargetEqual Weight$7.00 ➝ $2.50
1/5/2022CitigroupBoost TargetBuy ➝ Buy$30.00 ➝ $38.00
1/4/2022The Goldman Sachs GroupLower Target$10.00 ➝ $3.00
1/4/2022Robert W. BairdLower Target$35.00 ➝ $21.00
1/4/2022BarclaysDowngradeOverweight ➝ Equal Weight$44.00 ➝ $7.00
9/12/2021Robert W. BairdReiterated RatingBuy$35.00
8/26/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$16.00 ➝ $10.00
6/25/2021The Goldman Sachs GroupInitiated CoverageNeutral$18.00
3/21/2021Robert W. BairdReiterated RatingBuy$35.00
11/17/2020BarclaysLower Target$64.00 ➝ $44.00
10/8/2020Truist FinancialInitiated CoverageBuy$85.00 ➝ $85.00
6/17/2020CowenReiterated RatingBuy
4/22/2020The Goldman Sachs GroupInitiated CoverageBuy$60.00
3/3/2020CowenReiterated RatingBuy
2/27/2020BarclaysInitiated CoverageOverweight$64.00 ➝ $64.00
1/27/2020UBS GroupBoost TargetBuy$65.00
1/9/2020CitigroupBoost TargetBuy$29.00 ➝ $44.00
1/8/2020CowenReiterated RatingBuy
1/8/2020Robert W. BairdBoost TargetPositive ➝ Outperform$24.00 ➝ $43.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/24/2024
  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 10 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 8 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 11 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Applied Therapeutics logo
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Read More

Today's Range

Now: $9.43
Low: $8.82
High: $9.86

50 Day Range

MA: $8.32
Low: $4.65
High: $10.24

52 Week Range

Now: $9.43
Low: $1.79
High: $10.62

Volume

1,614,657 shs

Average Volume

1,832,252 shs

Market Capitalization

$1.10 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Applied Therapeutics?

The following equities research analysts have issued reports on Applied Therapeutics in the last twelve months: Citigroup Inc., Leerink Partners, Leerink Partnrs, Royal Bank of Canada, UBS Group AG, and William Blair.
View the latest analyst ratings for APLT.

What is the current price target for Applied Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Applied Therapeutics in the last year. Their average twelve-month price target is $12.50, suggesting a possible upside of 32.6%. Leerink Partners has the highest price target set, predicting APLT will reach $14.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $11.00 for Applied Therapeutics in the next year.
View the latest price targets for APLT.

What is the current consensus analyst rating for Applied Therapeutics?

Applied Therapeutics currently has 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APLT will outperform the market and that investors should add to their positions of Applied Therapeutics.
View the latest ratings for APLT.

What other companies compete with Applied Therapeutics?

Other companies that are similar to Applied Therapeutics include Avid Bioservices, Prothena, Dynavax Technologies, Rigel Pharmaceuticals and G1 Therapeutics. Learn More about companies similar to Applied Therapeutics.

How do I contact Applied Therapeutics' investor relations team?

Applied Therapeutics' physical mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company's listed phone number is (212) 220-9226 and its investor relations email address is [email protected]. The official website for Applied Therapeutics is www.appliedtherapeutics.com. Learn More about contacing Applied Therapeutics investor relations.